Melatonin is found to regulate the immunosuppressive tumor microenvironment (TME) by inhibiting the YAP/PD-L1 axis, and it may be a novel therapy for KRAS-mutant NSCLC [97]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.